Prosciento - Company Profile

Prosciento (formerly Profil Institute for Clinical Research) is a CRO exclusively focused on clinical trials targeting diabetes, obesity and NAFLD/NASH. It was initially a subsidiary of the German company "Profil" formed in 1999 by researchers at the University of Dusseldorf, Germany. The US subsidiary became an independent business in 2008 after a management buyout. The company claims to have experience in the development of small and large molecule therapies, including biologics and biosimilars through all routes of administration, as well as devices. Their Service Portfolio include: Clinical Development, Regulatory Affairs, Clinical Research, Scientific Services, Data Management and Statistical Services, Monitoring, Quality & Compliance Recruitment Services. The company is part of the Metabolic Research Partners™, offering scientific services for metabolic diseases at all stages of development. Profil Institute's metabolic expertise includes compounds such as Injectable and inhalable insulin, Immunomodulators, Alpha-glucosidase inhibitors, Incretin mimetics and several others. They also claim to have expertise in handling trials for devices such as Pumps, Glucose monitoring devices, Continuous glucose monitors and various types of drug delivery systems. Profil is the inventor of the Automated Clamp Technology to study the effect of drugs against diabetes with advantages such as "zero blood loss for the study participant"," blood glucose measurements in one or five-minute intervals", and the ability to perform 15+ experiments simultaneously. The company claims to have completed more than 280 metabolic clinical projects, including 245 clinical trials in diabetes, obesity and NAFLD/NASH.